CORBEL Catalogue of Services
Why do we need a Catalogue of Services?
Currently there are 13 biological and medical sciences Research Infrastructures (RIs) in Europe, all of them working jointly together in CORBEL towards offering shared services for life-science.
All RIs offer services, i.e. researchers from academia and industry can access their facilities, technologies and expertise. Services can simply be consultation, access to experts, but also access to data and biological samples, use of data analysis tools, access to facilities (e.g. highly specialised microscopes) plus support from technicians and much more.
The CORBEL Catalogue of Services is the first tool to list the main services of all these RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world.
The Catalogue of Services as displayed below aims to provide you a basic overview on existing services within distinct thematic fields.
You can either use the Catalogue of Services to identify a single RI to help you with your work or you can create your own CORBEL service pipelines, i.e. using several RIs subsequently.
Examples of service pipelines are provided here.
>> In order to improve the catalogue, we kindly ask you to fill in a short feedback form.
What’s your need?
Data & Databases
Technologies & Facilities
- accreditated/certified facilities (ISO certified, GLP, GMP, GCP)
- adaptation / development of assays (compounds etc.)
- adaptation / development of assays (human/non-human samples)
- high-throughput screening
- imaging (biological)
- imaging (medical)
- isolation / cultivation / characterisation of microorganisms
- -omics technology platforms
- plant phenotyping technologies/facilities
- production of high quality protein samples
- structural biology technologies/software
Models & Tools
Expertise & Support
- assessment of projects' impact and innovation potential
- biomarker validation
- biosecurity / biosafety (incl. regulatory) issues
- data management expertise
- development of project towards a medical application
- ethical / legal issues, informed consent
- mouse model generation, phenotyping and cryopreservation
- multinational clinical trial (establishment / management / monitoring)
- outbreak / emergency response / epidemiology
- support to submit a project proposal
- systems biology expertise
- training courses
- The following RIs offer complementary services:
Contact person(s): Project Manager: Dr. Tanja Miletic
EU-OPENSCREEN integrates high-capacity screening platforms throughout Europe, which jointly use a rationally selected compound collection, comprising up to 140.000 commercial and proprietary compounds collected from European chemists. EU-OPENSCREEN offers to researchers from academic institutions, SMEs and industrial organisations open access to its shared resources.
EU-OPENSCREEN will collaboratively develop novel molecular tool compounds with external users from various disciplines of the life sciences.
Services provided by EU-OPENSCREEN include
- high-throughput compound/ drug screening (HTS): HTS of an assay against the EU-OPENSCREEN chemical collection (> 100,000 compounds); in silico profiling; hit selection; confirmatory screening; basic counter screening; basic SAR based on screening data; QC of confirmed hits
- access to a unique European compound collection: EU-OPENSCREEN chemical collection (> 100,000 compounds)
- assay adaption: This assay adaptation process will involve a strong emphasis on quality, including: quality control of reagents; (patho-)physiological relevance; pharmacological consistency; robustness; minimised variability; and tracking of statistical descriptors (e.g. signal to background and the Z’ factor)
- chemical optimization and profiling of preliminary ‘hits’
- bioprofiling of donated compounds: All compounds donated by the user which enter the EU-OPENSCREEN ERIC compound collection are characterised and annotated for basic physico-chemical (e.g. identity, solubility, light absorbance and fluorescence) and essential to know biological properties (cytotoxicity, antibiotic, antifungal etc.) by testing in a standard panel of assays.
- provision of standardised data: All data generated through QC/bioprofiling and screening activities will be published in EU-OPENSCREEN’s open-access database with an optional ‘grace’ period (i.e. delayed publication of data). Large-scale open-access data provide the basis for computational data integration to obtain a systematic view, allow for prediction of drug-target interactions and networks as well as of adverse effects and drug combinations. The access to the EU-OPENSCREEN database will utilize the facilities of ChEMBL.
- training and education activities
Why to work with us
Please note: Most of the RIs are constantly developing their portfolio of services, so if you do not find the service/tool you are looking for, do not hesitate to contact the RI and ask for it!